Cargando…

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy without an available effective systemic chemotherapy. Insulin growth factor 2 (IGF-2) overexpression leading to the activation of the IGF-1 receptor (IGF-1R)/mammalian target of rapamycin (mTOR) pathway is well...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naing, A, LoRusso, P, Fu, S, Hong, D, Chen, H X, Doyle, L A, Phan, A T, Habra, M A, Kurzrock, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590681/ https://www.ncbi.nlm.nih.gov/pubmed/23412108 http://dx.doi.org/10.1038/bjc.2013.46

Ejemplares similares

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
por: Liu, Xiaochun, et al.
Publicado: (2016)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures
por: Subbiah, Vivek, et al.
Publicado: (2011)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
por: Qu, Xiao, et al.
Publicado: (2017)

A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
por: Trivedi, Neel D., et al.
Publicado: (2021)

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
por: Wilky, B A, et al.
Publicado: (2015)

Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer
por: Solomon, Viswas Raja, et al.
Publicado: (2020)

The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
por: Li, Shuyu, et al.
Publicado: (2013)

The role of mTOR pathway as target for treatment in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Cixutumumab reveals a critical role for IGF-1 in adipose and hepatic tissue remodelling during the development of diet-induced obesity
por: Imrie, Helen, et al.
Publicado: (2022)

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
por: Chiarini, Francesca, et al.
Publicado: (2012)

Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis
por: Qi, Wei-Xiang, et al.
Publicado: (2013)

Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions
por: Ushijima, Hiroki, et al.
Publicado: (2015)

Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
por: Chugh, R., et al.
Publicado: (2019)

Tissue-Specific Responses of IGF-1/Insulin and mTOR Signaling in Calorie Restricted Rats
por: Sharma, Naveen, et al.
Publicado: (2012)

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
por: Venugopal, Balaji, et al.
Publicado: (2013)

Temsirolimus Inhibits Proliferation and Migration in Retinal Pigment Epithelial and Endothelial Cells via mTOR Inhibition and Decreases VEGF and PDGF Expression
por: Liegl, Raffael, et al.
Publicado: (2014)

IGF1-Stimulated Posttraumatic Hippocampal Remodeling Is Not Dependent on mTOR
por: Littlejohn, Erica L., et al.
Publicado: (2021)

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
por: Hou, Ming-Mo, et al.
Publicado: (2014)

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
por: Boni, J P, et al.
Publicado: (2008)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2019)

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
por: Stockton, Shannon, et al.
Publicado: (2023)

IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers
por: Amin, Hesham M., et al.
Publicado: (2020)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

hNAG-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling
por: Wang, Xingya, et al.
Publicado: (2014)

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
por: Verschraegen, Claire F., et al.
Publicado: (2013)

IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients
por: Erbay, Ebru, et al.
Publicado: (2003)

Metastatic clear cell renal carcinoma – an unusual response to Temsirolimus in second line therapy
por: Stanculeanu, DL, et al.
Publicado: (2016)

Response to Letter to the Editor From Berruti et al: “Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival”
por: Srougi, Victor, et al.
Publicado: (2022)

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center
por: Afshar, Mehran, et al.
Publicado: (2014)

Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
por: Rangwala, Reshma, et al.
Publicado: (2014)

IGF2 role in adrenocortical carcinoma biology
por: Pereira, Sofia S., et al.
Publicado: (2019)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
por: Jimenez, Camilo, et al.
Publicado: (2022)

Ageing in Drosophila: The role of the insulin/Igf and TOR signalling network
por: Partridge, Linda, et al.
Publicado: (2011)

Evaluating the activity of temsirolimus in neuroendocrine cancer
por: O'Donnell, P H, et al.
Publicado: (2007)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_opm323hs9eau4pvnlr0ag18sh4